Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study
2024

Patient Outcomes of Rezvilutamide vs Bicalutamide in Prostate Cancer

Sample size: 654 publication 10 minutes Evidence: high

Author Information

Author(s): Wang Hongkai, Jiang Shusuan, Luo Hong, Zhou Fangjian, He Dalin, Ma Lulin, Guo Hongqian, Liang Chaozhao, Chong Tie, Jiang Jun, Chen Zhiwen, Wang Yong, Zou Qing, Tian Ye, Xiao Jun, Huang Jian, Chen Jinchao, Dong Qiang, Zhang Xiaoping, Li Hanzhong, Yang Xinfeng, Lian Jianpo, Wang Wenliang, Ye Dingwei

Primary Institution: Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China

Hypothesis

Does rezvilutamide combined with androgen deprivation therapy improve patient-reported outcomes compared to bicalutamide in high-volume metastatic hormone-sensitive prostate cancer patients?

Conclusion

Rezvilutamide combined with androgen deprivation therapy significantly improves pain management and functional outcomes compared to bicalutamide in patients with high-volume metastatic hormone-sensitive prostate cancer.

Supporting Evidence

  • Patients treated with rezvilutamide experienced a longer time to progression of worst pain intensity compared to those on bicalutamide.
  • Rezvilutamide showed a significant delay in the deterioration of functional health as measured by the FACT-P questionnaire.
  • Both treatment groups had comparable baseline characteristics, ensuring a fair comparison.

Takeaway

This study shows that a new medicine called rezvilutamide helps people with prostate cancer feel less pain and stay active longer than an older medicine called bicalutamide.

Methodology

Patients were randomly assigned to receive either rezvilutamide or bicalutamide with androgen deprivation therapy, and patient-reported outcomes were assessed using specific questionnaires.

Potential Biases

Potential bias due to the study being conducted in a specific demographic and the exploratory nature of patient-reported outcomes.

Limitations

The follow-up duration may not fully capture long-term patient-reported outcomes, and the study population was predominantly Asian, which may limit generalizability.

Participant Demographics

Patients were men aged 18 and older with high-volume metastatic hormone-sensitive prostate cancer, primarily Asian.

Statistical Information

P-Value

p=0.002

Confidence Interval

95% CI 7.4–20.3

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/s41392-024-02064-z

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication